UNSPSC 51295301: Alnespirone

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C26H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34E28BM822, chemically known as 8-azaspiro(4.5)decane-7,9-dione, 8-(4-((3,4-dihydro-5-methoxy-2h-1-benzopyran-3-yl)propylamino)butyl)-, monohydrochloride, (s)- but generally known as alnespirone, which bears US NIH Compound Identifier 121851. European Medicines Agency schedules Alnespirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05353MIG.

UNSPSC 51295301 Alnespirone is a Commodity code with minimal recent state and local procurement activity directly aligned to it. The recent opportunities tagged under this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical programs — work that falls under broader pharmaceutical supply and distribution rather than alnespirone specifically. State and local governments buy pharmaceuticals, medical supplies, and pharmacy benefit services through this taxonomy tier, but the opportunities in the market right now do not target alnespirone as a distinct line item; instead, they pursue naloxone (an opioid antagonist), generic pharmaceuticals bundled through cooperative purchasing vehicles, and direct-to-manufacturer prescription fulfillment models.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP, serving state and local government participants across multiple jurisdictions including Oregon). Recent solicitations include IFB60459723LAS, a Seminole County IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; HHS0017013, a Texas HHS Request for Information on direct-to-manufacturer prescription programs posted April 3, 2026; and S1070000015802, MMCAP's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, serving state and local facilities across multiple states. Activity is concentrated in Florida and Texas, with multistate cooperative purchasing extending into Oregon and other MMCAP member jurisdictions. The code shows low specificity to alnespirone; firms pursuing pharmaceutical procurement at the state and local level should monitor this code for broader pharmaceutical supply opportunities but should not expect consistent alnespirone-specific demand signals.